Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 3/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 10/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21630393 | 0.88 | FYN (0.48) | ACVR1NOD2MEN1KMT2APOLB | |
| SCHEMBL20523675 | 0.86 | RIPK2 (0.50) | ACVR1NOD2MEN1KMT2APOLB | |
| SCHEMBL21630446 | 0.83 | NOD2 (0.62) | ACVR1NOD2MEN1KMT2APOLB | |
| SCHEMBL21630351 | 0.82 | PIK3CG (0.48) | ACVR1NOD2MEN1KMT2APOLB | |
| SCHEMBL20523471 | 0.80 | NOD2 (0.48) | ACVR1NOD2MEN1KMT2APOLB | |
| SCHEMBL20523673 | 0.79 | RIPK2 (0.59) | ACVR1NOD2MEN1KMT2APOLB | |
| SCHEMBL20523604 | 0.77 | MAPT (0.37) | KMT2ABRAF | |
| SCHEMBL31720954 | 0.76 | FYN (0.56) | ACVR1NOD2MEN1KMT2APOLB | |
| SCHEMBL26851098 | 0.76 | FYN (0.56) | ACVR1NOD2MEN1KMT2APOLB | |
| SCHEMBL20523469 | 0.75 | FYN (0.50) | ACVR1NOD2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3600307-B1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | UNIV HOUSTON SYSTEM (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3600307-A1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | University of Houston System (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2018183633-A1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | RIPK2, RIPK1, NOD2 | ACVR1 8/4885NOD2 3/4885MEN1 2285/4885 |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | RIPK2, RIPK1, NOD2 | ACVR1 8/4885NOD2 3/4885MEN1 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.